Down syndrome screening: Difference between revisions

Jump to navigation Jump to search
 
(2 intermediate revisions by the same user not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Down syndrome}}
{{Down syndrome}}
{{CMG}}
{{CMG}}; {{AE}}{{HK}}
==Overview==
==Overview==
Standard prenatal screens can discover Down syndrome. [[Genetic counseling]] along with [[genetic testing]], such as [[amniocentesis]], [[chorionic villus sampling]] (CVS), or percutaneous umbilical blood sampling (PUBS) are usually offered to families who may have an increased risk of having a child with [[Down syndrome]], or where normal [[prenatal]] exams indicate possible problems. [[Genetic]] [[Screening (medicine)|screens]] are often performed on [[pregnant]] women older than 30 or 35. During the [[first trimester]] of [[pregnancy]], increased [[nuchal translucency]] in the [[fetus]] on [[ultrasound]] and decreased levels of pregnancy associated protein- A (PAPP-A) suggest the diagnosis of a [[chromosomal]] abnormality. [[Quad screen]] results during the [[second trimester]] of [[pregnancy]] may show increased [[beta-hCG]], increased [[inhibin A]], decreased [[Alpha-fetoprotein|alfa-fetoprotein]] ([[Alpha-fetoprotein|AFP]]) and decreased [[estriol]].  
Standard prenatal screens can discover Down syndrome. [[Genetic counseling]] along with [[genetic testing]], such as [[amniocentesis]], [[chorionic villus sampling]] (CVS), or percutaneous umbilical blood sampling (PUBS) are usually offered to families who may have an increased risk of having a child with [[Down syndrome]], or where normal [[prenatal]] exams indicate possible problems. [[Genetic]] [[Screening (medicine)|screens]] are often performed on [[pregnant]] women older than 30 or 35. During the [[first trimester]] of [[pregnancy]], increased [[nuchal translucency]] in the [[fetus]] on [[ultrasound]] and decreased levels of pregnancy associated protein- A (PAPP-A) suggest the diagnosis of a [[chromosomal]] abnormality. [[Quad screen]] results during the [[second trimester]] of [[pregnancy]] may show increased [[beta-hCG]], increased [[inhibin A]], decreased [[Alpha-fetoprotein|alfa-fetoprotein]] ([[Alpha-fetoprotein|AFP]]) and decreased [[estriol]].  
Line 12: Line 12:
|+ Common first and second trimester Down syndrome screens
|+ Common first and second trimester Down syndrome screens
|-
|-
!Screen
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Screen
!When performed (weeks [[gestation]])
! align="center" style="background:#4479BA; color: #FFFFFF;" + |When performed (weeks gestation)
!Detection rate
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Detection rate
![[Type I and type II errors|False positive]] rate
! align="center" style="background:#4479BA; color: #FFFFFF;" + |False positive rate
!Description
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Description
|-
|-
|Triple screen
|Triple screen

Latest revision as of 06:43, 21 March 2018

Down syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Down syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Sociological and Cultural Aspects

Case Studies

Case #1

Down syndrome screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Down syndrome screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Down syndrome screening

CDC on Down syndrome screening

Down syndrome screening in the news

Blogs on Down syndrome screening

Directions to Hospitals Treating Down syndrome

Risk calculators and risk factors for Down syndrome screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Syed Hassan A. Kazmi BSc, MD [2]

Overview

Standard prenatal screens can discover Down syndrome. Genetic counseling along with genetic testing, such as amniocentesis, chorionic villus sampling (CVS), or percutaneous umbilical blood sampling (PUBS) are usually offered to families who may have an increased risk of having a child with Down syndrome, or where normal prenatal exams indicate possible problems. Genetic screens are often performed on pregnant women older than 30 or 35. During the first trimester of pregnancy, increased nuchal translucency in the fetus on ultrasound and decreased levels of pregnancy associated protein- A (PAPP-A) suggest the diagnosis of a chromosomal abnormality. Quad screen results during the second trimester of pregnancy may show increased beta-hCG, increased inhibin A, decreased alfa-fetoprotein (AFP) and decreased estriol.

Screening

Prenatal screening

  • Pregnant women can be screened for various complications during pregnancy. Many standard prenatal screens can discover Down syndrome. Genetic counseling along with genetic testing, such as amniocentesis, chorionic villus sampling (CVS), or percutaneous umbilical blood sampling (PUBS) are usually offered to families who may have an increased chance of having a child with Down syndrome, or where normal prenatal exams indicate possible problems. Genetic screens are often performed on pregnant women older than 30 or 35.
  • Amniocentesis and CVS are considered invasive procedures, in that they involve inserting instruments into the uterus, and therefore carry a small risk of causing fetal injury or miscarriage. There are several common non-invasive screens that can indicate a fetus with Down syndrome. These are normally performed in the late first trimester or early second trimester. Due to the nature of screens, each has a significant chance of a false positive, suggesting a fetus with Down syndrome when, in fact, the fetus does not have this genetic abnormality. Screen positives must be verified before a Down syndrome diagnosis is made. Common screening procedures for Down syndrome are given in Table 1.
Common first and second trimester Down syndrome screens
Screen When performed (weeks gestation) Detection rate False positive rate Description
Triple screen 15–20 75% 8.5% This test measures the maternal serum alpha feto protein (a fetal liver protein), estriol (a pregnancy hormone), and human chorionic gonadotropin (hCG, a pregnancy hormone).[1]
Quad screen 15–20 79% 7.5% This test measures the maternal serum alpha feto protein (a fetal liver protein), estriol (a pregnancy hormone), human chorionic gonadotropin (hCG, a pregnancy hormone), and high inhibin-Alpha (INHA).[1]
AFP/free beta screen 13–22 80% 2.8% This test measures the alpha feto protein, produced by the fetus, and free beta hCG, produced by the placenta.
Nuchal translucency/free beta/PAPPA screen 10–13.5 91%[2] 5%[2] Uses ultrasound to measure Nuchal Translucency in addition to the freeBeta hCG and PAPPA (pregnancy-associated plasma protein A). NIH has confirmed that this first trimester test is more accurate than second trimester screening methods.[3]

Postnatal Screening

Persons with Down syndrome need to be closely screened for certain medical conditions. They should have:

  • Eye exam every year during infancy
  • Hearing tests every 6 - 12 months, depending on age
  • Dental exams every 6 months
  • X-rays of the upper or cervical spine between ages 3 - 5 years
  • Pap smears and pelvic exams beginning during puberty or by age 21
  • Thyroid testing every 12 months

References

  1. 1.0 1.1 For a current estimate of rates, see Benn, PA, J Ying, T Beazoglou, JFX Egan. "Estimates for the sensitivity and false-positive rates for second trimester serum screening for Down syndrome and trisomy 18 with adjustments for cross-identification and double-positive results". Prenatal Diagnosis. 21 (1): 46–51. PMID 11180240
  2. 2.0 2.1 Some practices report adding Nasal Bone measurements and increasing the detection rate to 95% with a 2% False Positive Rate.
  3. NIH FASTER study (NEJM 2005 (353):2001). See also J.L. Simplson's editorial (NEJM 2005 (353):19).

Template:WH Template:WS